$VistaGen Therapeutics (VTGN.US)$ VistaGen Therapeutics GAAP EPS of -$1.52 misses by $1.16, revenue of $1.06M beats by $0.86M Jun. 11, 2024 4:23 PM ETVistagen Therapeutics, Inc. (VTGN) StockBy: Mary Christine Joy, SA News Editor VistaGen Therapeutics press release (NASDAQ:VTGN): Q4 GAAP EPS of -$1.52 misses by $1.16. Revenue of $1.06M (vs. -$0.23M last year) beats by $0.86M. Shares +0.8%. Registration-directed fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder...
VistaGen Therapeutics股票讨论
3.28买入5.2万只大鱼
Vistagen通过新专利扩大用于偏头痛治疗的Ph80全球知识产权组合
VistaGen Therapeutics GAAP EPS of -$1.52 misses by $1.16, revenue of $1.06M beats by $0.86M
Jun. 11, 2024 4:23 PM ETVistagen Therapeutics, Inc. (VTGN) StockBy: Mary Christine Joy, SA News Editor
VistaGen Therapeutics press release (NASDAQ:VTGN): Q4 GAAP EPS of -$1.52 misses by $1.16.
Revenue of $1.06M (vs. -$0.23M last year) beats by $0.86M.
Shares +0.8%.
Registration-directed fasedienol PALISADE Phase 3 program for the acute treatment of social anxiety disorder...
Vistagen报告称,24财年净亏损为2940万美元,而去年净亏损为5,920万美元
暂无评论